Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NORTH POLE DMD Phase II study of NPC-14 (arbekacin sulfate) in Duchenne muscular dystrophy
jRCT1091220134Phase 2Completed
- Sponsor
- Hyogo Medical University Hospital
- Start
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Duchenne muscular dystrophy (DMD) comparing NPC-14 (arbekacin) arm with Placebo arm (2 arms). Primary endpoints: Adverse events and Dystrophin expression. Started Aug 2013; status: completed.
02
Drugs
arbekacin
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on jRCT1091220134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1091220134.